Desidustat

Desidustat is a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) designed for the treatment of anemia associated with chronic kidney disease (CKD) and other hypoxia-related conditions. By mimicking the body's natural response to low oxygen levels, Desidustat stimulates the production of erythropoietin, a hormone responsible for red blood cell production.

Indications

Desidustat is indicated for the management of anemia associated with chronic kidney disease (CKD) in patients who are not undergoing dialysis.

Dosage

The recommended starting dosage of Desidustat is 25 mg orally once daily, which may be adjusted based on individual patient response and tolerability. Dosage adjustments should be made at intervals of 4 weeks or longer.

Contra-Indications

Desidustat is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Special Precautions

-Desidustat should be used with caution in patients with a history of cardiovascular disease or thromboembolic events. -Monitoring of hemoglobin levels and blood pressure is recommended during treatment with Desidustat. -Desidustat should be used cautiously in patients with hepatic impairment, as dosage adjustment may be necessary.

Side Effects

Common side effects of Desidustat include nausea, diarrhea, headache, and hypertension. Other less common side effects may include thromboembolic events, elevation of liver enzymes, and allergic reactions.

Drug Interactions

Desidustat may interact with other medications, including anticoagulants, antiplatelet agents, and drugs metabolized by CYP enzymes. Close monitoring and dosage adjustments may be necessary when Desidustat is co-administered with these drugs.